October 17, 2019, New York, NY
6:00 pm - 8:00 pm

Xeris Pharmaceuticals, Inc., has received regulatory approval from the U.S. Food and Drug Administration (FDA) for GVOKE™ (glucagon) injection, its ready-to-use, room-temperature stable liquid glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above.

Everyone managing diabetes is at risk for developing severely low blood sugar, or hypoglycemia, and we know this can quickly progress from a mild event to an emergency. The availability of GVOKE – the first ready-to-use liquid glucagon option – brings confidence to patients, parents and caregivers that these challenging events can be easily and rapidly resolved.

GVOKE is the first glucagon product approved that can be administered via a prefilled syringe (GVOKE PFS) or auto-injector (GVOKE HypoPen™), vastly reducing the steps to prepare and administer glucagon in the event of severe hypoglycemia, or dangerously low blood sugar levels. These innovative formats are designed to provide the reliability of a ready-to-use liquid glucagon while making it easier for patients or caregivers to administer quickly and simply. GVOKE will be available in two doses: a 0.5 mg/0.1 mL dose for pediatric patients and a 1 mg/0.2 mL dose for adolescent and adult patients.

Join us for a discussion on this innovative product!

Samuel S. Grossman, BS. Pharm, Pharm.D. CDE FAADE will present information on behalf of Xeris Pharmaceuticals, on the new approved GVOKE (glucagon), prefilled syringe. Join us to learn about this glucagon treatment option, including its efficacy, usability, safety and an opportunity to ask questions about the information presented. Dinner will be served. RSVP is required to Samantha Rogers, Outreach Manager at srogers@jdrf.org or 212.478.4314.